Nigel Mackman Selected Research

Thrombin

1/2022	Direct Oral Anticoagulants and Coronary Artery Disease.
1/2022	Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice.
1/2021	Host fibrinogen drives antimicrobial function in Staphylococcus aureus peritonitis through bacterial-mediated prothrombin activation.
1/2021	Platelet-Mediated NET Release Amplifies Coagulopathy and Drives Lung Pathology During Severe Influenza Infection.
1/2021	Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.
1/2021	Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment.
1/2020	Neutrophils and neutrophil extracellular traps enhance venous thrombosis in mice bearing human pancreatic tumors.
6/2019	Tissue Factor and Cancer: Regulation, Tumor Growth, and Metastasis.
1/2019	Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival.
1/2018	The red blood cell death receptor and thrombosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nigel Mackman Research Topics

Disease

83	Thrombosis (Thrombus) 11/2022 - 03/2003
50	Neoplasms (Cancer) 11/2022 - 02/2005
36	Inflammation (Inflammations) 01/2022 - 10/2003
20	Hemorrhage 07/2022 - 04/2005
20	Venous Thrombosis (Deep-Vein Thrombosis) 01/2022 - 02/2009
19	Infections 11/2021 - 03/2003
13	Venous Thromboembolism 07/2022 - 12/2006
12	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 06/2012
11	Atherosclerosis 01/2022 - 07/2002
10	Sepsis (Septicemia) 05/2021 - 08/2002
10	Endotoxemia 02/2017 - 01/2003
9	COVID-19 02/2022 - 01/2020
9	Ischemia 01/2022 - 02/2003
8	Atherosclerotic Plaque (Atheroma) 01/2020 - 08/2005
7	Rupture 01/2018 - 03/2003
6	Virus Diseases (Viral Diseases) 11/2021 - 05/2008
6	Neoplasm Metastasis (Metastasis) 06/2019 - 02/2005
6	Infarction (Infarctions) 01/2018 - 02/2003
6	Hypoxia (Hypoxemia) 11/2017 - 03/2003
6	Reperfusion Injury 11/2017 - 02/2003
5	Disseminated Intravascular Coagulation 11/2021 - 01/2003
5	Glioma (Gliomas) 01/2021 - 07/2006
5	Heart Failure 01/2021 - 11/2007
5	Necrosis 01/2018 - 03/2009
5	Sickle Cell Anemia (Hemoglobin S Disease) 11/2017 - 07/2012
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2017 - 10/2003
4	Thromboembolism 05/2022 - 01/2010
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 02/2012
4	Fibrosis (Cirrhosis) 01/2021 - 03/2007
4	Myocardial Infarction 01/2018 - 11/2007
3	Hypertrophy 01/2021 - 11/2007
3	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2010
3	Stroke (Strokes) 01/2020 - 07/2016
3	Hyperlipidemias (Hyperlipidemia) 01/2015 - 05/2012
3	Glioblastoma (Glioblastoma Multiforme) 11/2014 - 07/2006

Drug/Important Bio-Agent (IBA)

127	Thromboplastin (Tissue Factor)IBA 11/2022 - 07/2002
33	Thrombin FDA Link 01/2022 - 02/2003
27	Proteins (Proteins, Gene)FDA Link 11/2022 - 03/2003
22	FibrinIBA 05/2021 - 01/2003
20	AnticoagulantsIBA 01/2022 - 02/2004
20	Biomarkers (Surrogate Marker)IBA 11/2021 - 03/2009
13	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 02/2004
12	fibrin fragment D (D-dimer)IBA 11/2021 - 07/2012
11	Hemostatics (Antihemorrhagics)IBA 01/2022 - 03/2006
9	CytokinesIBA 01/2020 - 02/2003
9	LipopolysaccharidesIBA 01/2019 - 08/2002
9	Proteinase-Activated ReceptorsIBA 01/2019 - 02/2004
7	Messenger RNA (mRNA)IBA 11/2021 - 03/2003
7	Factor VIIa (Activated Factor VII)IBA 01/2020 - 05/2004
6	Factor Xa (Coagulation Factor Xa)IBA 01/2022 - 09/2012
6	AntithrombinsIBA 01/2022 - 12/2006
6	Interleukin-6 (Interleukin 6)IBA 10/2021 - 05/2004
6	Fibrinogen (Factor I)FDA Link 01/2021 - 05/2003
6	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2015 - 10/2008
5	LDL Receptors (LDL Receptor)IBA 01/2022 - 03/2006
5	AntibodiesIBA 11/2021 - 10/2007
5	Plasminogen Activator Inhibitor 1IBA 10/2021 - 10/2011
5	Plasminogen Activators (Plasminogen Activator)IBA 01/2021 - 11/2006
5	NF-kappa B (NF-kB)IBA 08/2009 - 08/2002
4	RivaroxabanIBA 01/2022 - 01/2018
4	RNA (Ribonucleic Acid)IBA 11/2021 - 04/2014
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021 - 08/2002
4	Monoclonal AntibodiesIBA 01/2021 - 02/2003
4	Histones (Histone)IBA 11/2020 - 12/2019
4	ferric chlorideIBA 05/2020 - 01/2009
4	Complement System Proteins (Complement)IBA 01/2020 - 10/2007
4	LipidsIBA 01/2020 - 09/2005
4	Transcription Factors (Transcription Factor)IBA 06/2019 - 08/2002
4	PAR-2 ReceptorIBA 06/2019 - 10/2008
4	Pharmaceutical PreparationsIBA 01/2018 - 05/2009
4	estropipate (Ogen)FDA LinkGeneric 08/2017 - 05/2003
4	P-SelectinIBA 01/2017 - 12/2006
4	PolyphosphatesIBA 04/2016 - 04/2014
4	ChemokinesIBA 01/2011 - 02/2003
3	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2022 - 09/2015
3	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 09/2015
3	Factor Xa InhibitorsIBA 01/2022 - 01/2018
3	Apolipoproteins E (ApoE)IBA 01/2022 - 03/2006
3	ApolipoproteinsIBA 01/2022 - 03/2006
3	Fibrinolysin FDA Link 05/2021 - 01/2021
3	InterferonsIBA 01/2021 - 05/2008
3	Glycoproteins (Glycoprotein)IBA 01/2020 - 09/2005
3	Factor XIa (Coagulation Factor XIa)IBA 01/2020 - 04/2016
3	IntegrinsIBA 06/2019 - 04/2013
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2019 - 03/2003
3	Antiphospholipid AntibodiesIBA 02/2019 - 10/2008
3	Factor XI (Plasma Thromboplastin Antecedent)IBA 01/2019 - 08/2011
3	AnthracyclinesIBA 01/2018 - 07/2010
3	CholesterolIBA 01/2018 - 02/2012
3	PAR-1 ReceptorIBA 01/2018 - 11/2011
3	Factor XII (Hageman Factor)IBA 09/2015 - 04/2012
3	oxidized low density lipoproteinIBA 01/2015 - 02/2012
3	epidermal growth factor receptor VIIIIBA 11/2014 - 12/2008
3	Biological ProductsIBA 05/2014 - 03/2009
3	Antiviral Agents (Antivirals)IBA 04/2014 - 05/2008
3	CoagulantsIBA 04/2014 - 07/2012
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 03/2009 - 08/2002

Therapy/Procedure

21	Therapeutics 01/2022 - 05/2003
8	Drug Therapy (Chemotherapy) 11/2021 - 01/2010
7	Ligation 01/2021 - 07/2002